Sequential Skin debuts Sequential Bio – the world’s first in-vivo microbiome testing solution for skin, hair, and personal product industries.
LONDON, NEW YORK and SINGAPORE, March 3, 2022 /PRNewswire/ -- Sequential Skin Ltd, a leading microbiome company today announced the debut of Sequential Bio – a novel "in-vivo" microbiome testing solution uniquely tailored for companies across skincare, haircare, and personal care product industries. Sequential Skin debuts Sequential Bio – the...
Akeso Announces Clinical Trial Collaboration with Chipscreen Biosciences to Evaluate Cadonilimab in Combination with Chiauranib for Extensive-Stage Small-Cell Lung Cancer
HONG KONG, March 2, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of innovative antibody drugs that are affordable to patients worldwide today announced that it has entered into a collaboration agreement with Shenzhen Chipscreen Biosciences, Ltd. (SHA Code 688321) to conduct a Phase Ib/II clinical study of combination therapy...
Zhongshan Chenxinghai Hospital, Hong Kong Integrated Oncology Centre and healthcare distributor DCH Auriga partner to provide Hong Kong-approved medical treatments to GBA patients
HONG KONG, March 2, 2022 /PRNewswire/ -- On 2 March 2022, Zhongshan Chenxinghai Hospital, a leading Hong Kong cancer treatment centre, Hong Kong Integrated Oncology Centre ("HKIOC"), and healthcare distributor DCH Auriga announced their strategic cooperation in support of a National State Council initiative to help patients in the Hong Kong-Guangzhou-Macao Greater Bay Area ("GBA") access pharmaceuticals and medical...
Seegene appoints Richard Creager as CEO of U.S. subsidiary to bolster U.S. business
SEOUL, South Korea, March 2, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today announced the appointment of Richard S. Creager, Ph.D., as the CEO of its United States subsidiary, Seegene Technologies. Dr. Creager brings decades of real-world in vitro diagnostics business and molecular diagnostics (MDx) experience...
Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates
SAN DIEGO and SUZHOU, China, Mar. 2, 2022 /PRNewswire/ -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced a collaboration and exclusive license agreement with Sanofi to generate masked monoclonal and bispecific antibodies for development and commercialization by Sanofi. Under the terms of the agreement, Adagene will be responsible for...
Intellect offers free access to healthcare workers to support mental well-being during surge in healthcare demand
SINGAPORE, March 2, 2022 /PR Newswire/ -- Singapore-based mental health platform Intellect is providing three-month premium access to healthcare workers in Singapore at no cost, aiming to help maintain their mental well-being. The self-care app company recognizes the importance of managing the psychological stress of frontline health workers who have been stretched throughout the COVID-19 pandemic. "As a nation,...
REDCLOUD BIO ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR NEXT-GENERATION EGFR INHIBITOR H002 IN NON-SMALL CELL LUNG CANCER
Drug Candidate Is First From Company To Enter Phase I/IIa Clinical Trial H002 Has Potential To Overcome Resistance Driven By Various EGFR C797S-Containing Mutations in Non-Small Cell Lung Cancer SHANGHAI, March 2, 2022 /PRNewswire/ -- RedCloud Bio (the "Company"), an innovative biotech company integrating structural pharmacology and computational approaches...
Four new leaders join Cargill’s executive team, aligned to company’s innovation strategy and customer priorities
MINNEAPOLIS, March 2, 2022 /PRNewswire/ -- Four new leaders are joining Cargill's executive team. They were selected for their expertise aligned to evolving customer and employee needs and their potential to drive the company's innovation and sustainability strategies around the world. "The food system is constantly and quickly changing. To continue delivering...
AKESO ANNOUNCED COLLABORATION WITH CHIPSCREEN BIOSCIENCES TO INITIATED A CLINICAL TRIAL OF PD-1/CTLA-4 BI-SPECIFIC ANTIBODY IN COMBINATION WITH CHIAURANIB FOR PD-(L)1 PRETREATED ES-SCLC
HONG KONG, March 1, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of new innovative antibody drugs that are affordable to patients worldwide announced that it entered into a collaboration agreement with Shenzhen Chipscreen Biosciences Co., Ltd., a company listed on the Shanghai Stock Exchange (Stock code: 688321.SH) (Chipscreen...
InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of NMOSD in China
BEIJING, March 2, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the Investigational New Drug (IND) approval of its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib by China National Medical Products Administration (NMPA) to start phase II clinical trial in Neuromyelitis Optica Spectrum Disorder (NMOSD) in China. This is a randomized, double-blind, placebo-controlled phase II...
